4.8 Article

Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation

期刊

CANCER CELL
卷 34, 期 1, 页码 56-+

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2018.05.014

关键词

-

资金

  1. NIH [DP5OD019787, 5T32 CA177555]
  2. Sandler Foundation
  3. Program for Breakthrough Biomedical Research
  4. UCSF Resource Allocation Program
  5. Melanoma Research Alliance [400991]
  6. NCI Outstanding Investigatory Award [1R35CA220481]
  7. NATIONAL CANCER INSTITUTE [T32CA177555, R35CA220481, K22CA217997] Funding Source: NIH RePORTER
  8. OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD019787] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Loss of the CDKN2A tumor suppressor is associated with melanoma metastasis, but the mechanisms connecting the phenomena are unknown. Using CRISPR-Cas9 to engineer a cellular model of melanoma initiation from primary human melanocytes, we discovered that a lineage-restricted transcription factor, BRN2, is downstream of CDKN2A and directly regulated by E2F1. In a cohort of melanocytic tumors that capture distinct progression stages, we observed that CDKN2A loss coincides with both the onset of invasive behavior and increased BRN2 expression. Loss of the CDKN2A protein product p16(INK4A) permitted metastatic dissemination of human melanoma lines in mice, a phenotype rescued by inhibition of BRN2. These results demonstrate a mechanism by which CDKN2A suppresses the initiation of melanoma invasion through inhibition of BRN2.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据